AcelRx Pharmaceuticals Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares

 AcelRx Pharmaceuticals Announces Closing Of Public Offering And Exercise Of
                     Option To Purchase Additional Shares

PR Newswire

REDWOOD CITY, Calif., July 23, 2013

REDWOOD CITY, Calif., July 23, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), today announced the closing of the public offering of
4,370,000 shares of common stock, including 570,000 shares of common stock
which were issued pursuant to the exercise of the underwriters' option to
purchase additional shares, at a price of $11.65 per share to the public.The
total gross proceeds of this offering were approximately $50.9 million with
estimated net proceeds to AcelRx of $47.9 million after deducting underwriting
discounts and commissions and other estimated expenses payable by AcelRx.

Jefferies LLC and Piper Jaffray & Co. acted as joint book-running managers for
the offering, and Guggenheim Securities acted as co-manager for the offering.

A shelf registration statement on Form S-3 relating to the public offering of
the shares of common stock described above was filed with the Securities and
Exchange Commission (the "SEC") and is effective. A final prospectus
supplement relating to the offering was filed with the SEC and is available on
the SEC's web site at Copies of the final prospectus supplement
may be obtained from the offices of Jefferies LLC, Equity Syndicate Prospectus
Department, at 520 Madison Avenue, New York, New York, 10022, or by calling
(877) 547-6340, or by emailing, or from
Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall,
J12S03, Minneapolis, MN 55402 or by calling (800)747-3924, or by emailing

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. 

Forward-Looking Information is Subject to Risk and Uncertainty
Certain of the statements made in this press release are forward looking, such
as those, among others, relating to AcelRx's expectations regarding the
anticipated proceeds from the sale of shares in the offering. Actual results
or developments may differ materially from those projected or implied in these
forward-looking statements. AcelRx will need to raise additional capital to
fund its operations and may be unable to raise capital when needed, which
would force AcelRx to delay, reduce or eliminate its product development
programs or commercialization efforts. You should not place undue reliance on
these forward-looking statements, which apply only as of the date of this
press release. Additional risks and uncertainties relating to AcelRx and its
business can be found under the heading "Risk Factors" in the Current Report
on Form 8-K filed with the SEC on July 19, 2013. AcelRx expressly disclaims
any obligation or undertaking to release publicly any updates or revisions to
any forward-looking statements contained herein to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based.


SOURCE AcelRx Pharmaceuticals, Inc.

Contact: Jim Welch, Chief Financial Officer, 650.216.3511,
Press spacebar to pause and continue. Press esc to stop.